相关实验视频

Updated: May 22, 2025

Structural Characterization of Mannan Cell Wall Polysaccharides in Plants Using PACE

Structural Characterization of Mannan Cell Wall Polysaccharides in Plants Using PACE

Published on: October 16, 2017

一种新型Moringa oleifera的结构特征和发酵,其叶子是具有降糖效应的多糖体

Yuxi Wen¹, Yang Zhou², Jiaxiang Xu²

¹College of Marine Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China; University of Vigo, Nutrition and Bromatology Group, Department of Analytical Chemistry and Food Science, Faculty of Science, E32004 Ourense, Spain.

|March 16, 2025

概括

莫林加橄树叶多糖化物 (MOP-3) 被分离和表征. 这种天然化合物调节肠道微生物群,增强有益的短链脂肪酸,增强肠道激素分泌,为代谢障碍管理提供了潜力.

科学领域:

食品科学与技术食品科学与技术
营养生物化学营养生物化学
微生物学微生物学

背景情况:

Moringa oleifera被认为具有健康益处,特别是在代谢障碍方面.
其多糖的结构细节和生物活性,特别是消化后的生物活性,尚未完全理解.
多糖对肠道微生物群和葡萄糖调节的影响需要进一步研究.

研究的目的:

从Moringa oleifera叶子中分离和结构性地表征一种低血糖多糖化物 (MOP-3).
研究MOP-3对肠道微生物群组成和功能的影响.
评估MOP-3对葡萄糖类-1 (GLP-1) 分泌及其低血糖潜力的影响.

主要方法:

从Moringa oleifera叶子中分离和净化多糖.
综合性结构分析,包括分子量测定和糖链路的识别.
在体外测试中使用STC-1细胞评估GLP-1分泌和肠道微生物群分析.

主要成果:

一种低血糖的多糖化合物MOP-3被分离出来,主要由阿拉比诺斯,拉姆诺斯和银糖组成 (MW:2.019 × 10^4 Da).
在MOP-3中确定了特定的甘氨酸链接,提供了结构性见解.
MOP-3改变了肠道微生物群的组成 (减少了Firmicutes,增加了Bacteroidetes和Proteobacteria),刺激了短链脂肪酸 (SCFA) 的产生,并增强了GLP-1的分泌.

结论:

描述的MOP-3表现出显著的低血糖特性.
MOP-3调节肠道微生物群和增强GLP-1分泌的能力支持其治疗潜力.
这项研究为利用Moringa oleifera多糖在食品和代谢健康的治疗应用提供了基础.

关键词:

糖尿病糖尿病糖尿病肠道健康肠道健康在体外发酵发酵.莫林加油的多糖化合物Moringa oleifera多糖

更多相关视频

Author Spotlight: MAPP Protocol – Advancing Glycan Analysis

Author Spotlight: MAPP Protocol – Advancing Glycan Analysis

Published on: September 29, 2023

Automated Modular High Throughput Exopolysaccharide Screening Platform Coupled with Highly Sensitive Carbohydrate Fingerprint Analysis

Automated Modular High Throughput Exopolysaccharide Screening Platform Coupled with Highly Sensitive Carbohydrate Fingerprint Analysis

Published on: April 11, 2016

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Carbohydrate Digestion

Carbohydrate Digestion

Carbohydrate digestion and metabolism break down simple and complex carbohydrates from food into saccharides (i.e., sugars) for the body to use as energy. Carbohydrate digestion starts in the mouth during mastication, or chewing. The masticated carbohydrates remain intact in the stomach. Digestion resumes in the duodenum of the small intestine, where pancreatic alpha-amylase and brush border enzymes of the microvilli convert complex carbohydrates to monosaccharides. Finally, the monosaccharides...